STOCKHOLM, July 8, 2019 /PRNewswire/ -- On 17 July, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the second quarter 2019. Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 09:00 am CEST (Please note the updated time this quarter). The event will be hosted by Sobi's CEO and President, Guido Oelkers, and the presentation will be held in English.

The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi's website prior to the telephone conference.

To participate in the telephone conference, please call:

SE: +46-8-505-583-55

UK: +44-33-330-090-30

US: +1-646-7224-957

Click here to go to the live webcast.

After the live event the webcast will be available on-demand via the same URL.

About Sobi™

At Sobi, we are transforming the lives of people affected by rare diseases. As a specialised international biopharmaceutical company, we provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases – a belief in the strength of focus, the power of agility and the potential of the people we are dedicated to serving. The hard work and dedication of our approximately 1,050 employees around the globe has been instrumental in our success across Europe, North America, the Middle East, Russia and North Africa, leading to total revenues of SEK 9.1 billion in 2018. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com.

For more information please contact

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/invitation---presentation-of-sobi-s-q2-2019-results,c2859367

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/invitation--presentation-of-sobis-q2-2019-results-300880636.html

SOURCE Swedish Orphan Biovitrum AB